Literature DB >> 19155346

Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.

Nancy L Borja-Hart1, Sandra Benavides, Crystal Christensen.   

Abstract

Recent news reports have linked the human papillomavirus (HPV) vaccine to serious adverse events (AEs) in children and adolescents. We used the Vaccine Adverse Event Reporting System (VAERS) database to extract postmarketing AEs reported in patients who received the vaccine. Since approval of the HPV vaccine in the US, 3174 AEs occurring in children and adolescents (aged 6-17 y) have been reported to the VAERS. Of these, 191 (6%) were deemed to be serious. Although these AEs are of significant concern, more research is required before they can be directly correlated with the vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155346     DOI: 10.1345/aph.1L492

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  6 in total

Review 1.  Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.

Authors:  Liisa K Selin; Myriam F Wlodarczyk; Anke R Kraft; Siwei Nie; Laurie L Kenney; Roberto Puzone; Franco Celada
Journal:  Autoimmunity       Date:  2011-01-20       Impact factor: 2.815

2.  Evaluation of optic neuritis following human papillomavirus vaccination.

Authors:  Gayathri Sridhar; Fang Tian; Richard Forshee; Martin Kulldorff; Nandini Selvam; Andrea Sutherland; Wilson Bryan; Samuel Barone; Lei Xu; Hector S Izurieta
Journal:  Hum Vaccin Immunother       Date:  2017-05-02       Impact factor: 3.452

Review 3.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.

Authors:  Paul L McCormack; Elmar A Joura
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

4.  Ischaemic stroke and influenza A H1N1 vaccination: a case report.

Authors:  Yi-Pin Lin; Tzu-Hui Li; Wei-Hsi Chen
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

Review 5.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

6.  Answering human papillomavirus vaccine concerns; a matter of science and time.

Authors:  David Hawkes; Candice E Lea; Matthew J Berryman
Journal:  Infect Agent Cancer       Date:  2013-06-12       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.